Pathophysiology, Diagnosis, and Management of Dyslipidemia

Gerald T. Gau, R. Scott Wright

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.

Original languageEnglish (US)
Pages (from-to)445-486
Number of pages42
JournalCurrent Problems in Cardiology
Volume31
Issue number7
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Dyslipidemias
Atherosclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Secondary Prevention
Lipoproteins
Pathologic Constriction
Ischemia
Kidney
Lipids
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pathophysiology, Diagnosis, and Management of Dyslipidemia. / Gau, Gerald T.; Wright, R. Scott.

In: Current Problems in Cardiology, Vol. 31, No. 7, 01.07.2006, p. 445-486.

Research output: Contribution to journalArticle

@article{62c4d475d2c04295a929e01a7d4c8a37,
title = "Pathophysiology, Diagnosis, and Management of Dyslipidemia",
abstract = "Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90{\%} statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.",
author = "Gau, {Gerald T.} and Wright, {R. Scott}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.cpcardiol.2006.03.001",
language = "English (US)",
volume = "31",
pages = "445--486",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - Pathophysiology, Diagnosis, and Management of Dyslipidemia

AU - Gau, Gerald T.

AU - Wright, R. Scott

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.

AB - Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.

UR - http://www.scopus.com/inward/record.url?scp=33745638548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745638548&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2006.03.001

DO - 10.1016/j.cpcardiol.2006.03.001

M3 - Article

C2 - 16824902

AN - SCOPUS:33745638548

VL - 31

SP - 445

EP - 486

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

IS - 7

ER -